Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (NASH/NAFLD (non-alcoholic fatty liver disease))
18 déc. 2019 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
-- MAESTRO-NAFLD-1 is the second resmetirom Phase 3 clinical trial in patients with NASH and presumed NASH and follows MAESTRO-NASH, a Phase 3 multi-center, double-blind, randomized,...
Madrigal Pharmaceuticals Announces Pricing of Secondary Offering
10 déc. 2019 23h57 HE
|
Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the...
Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)
11 nov. 2019 17h30 HE
|
Madrigal Pharmaceuticals, Inc.
Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH: demonstrated that resmetirom treatment resulted in statistically...
Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights
07 août 2019 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
-- Phase 3 MAESTRO-NASH Program Continues to Progress -- -- Jim Daly Added to Board of Directors and Becky Taub Promoted to President of R&D -- -- Madrigal Presentations Selected...
Madrigal Pharmaceuticals Promotes Rebecca Taub, M.D., Chief Medical Officer and Executive Vice President of Research & Development, to Newly Created Position of President of Research & Development
11 juil. 2019 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
-- Dr. Taub to present at the 5th Paris NASH Meeting to be held on July 11-12, 2019 -- CONSHOHOCKEN, Pa., July 11, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced...
Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors
02 juil. 2019 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., July 02, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Jim Daly has been appointed to the Company’s Board of Directors, as a Class I...
Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences
04 juin 2019 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 04, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Paul Friedman, M.D., Chief Executive Officer of Madrigal, and Becky Taub, M.D.,...
Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights
08 mai 2019 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., May 08, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2019 financial results and highlights: “Madrigal continued to make...
Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019
08 avr. 2019 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
-- MRI-PDFF response (≥30% reduction in hepatic fat) at 12 weeks correlated with reduction in the ballooning and inflammation components of NAS and was predictive of NASH resolution on liver biopsy at...
Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
28 mars 2019 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
-- Investigator meeting held March 21/22, 2019 -- -- In Phase 2 study resmetirom was statistically significantly superior to placebo in resolving NASH on biopsy, appeared safe and was well-tolerated...